Through measurement of PTX3 expression levels might provide prognostic information about HNSCC metastasis, which leads PTX3 a novel therapeutic target for EGFR-overexpressing HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.